BRCA1 and ovarian carcinoma: The importance of BRCA1/2 mutation screening in ovarian cancer patients has been further underscored by recent findings showing that mutation carriers have increased sensitivity to inhibitors of poly (ADP-ribose) polymerase (PARP) [2, 3].